



ASX Announcement

10 November 2021

Invex to Present at Bell Potter Healthcare Conference

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (once weekly extended release Exenatide) for neurological conditions relating to raised intracranial pressure, is pleased to advise that Dr Tom Duthy, Executive Director of Invex, will give a presentation at the Bell Potter Healthcare Conference on 11 November 2021 at 9.00am-9.30am AEDT.

A copy of the presentation is attached.

The Bell Potter virtual healthcare conference is designed to showcase the most exciting opportunities within the ASX healthcare sector for investors. The conference is well attended by Bell Potter's sizeable network of domestic and offshore institutional investors, domestic retail investors and retail advisers. The virtual setup also enables greater participation from Bell Potter's client base in Asian, European and US markets who are active in the ASX healthcare sector.

This release dated 10 November 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

ENDS

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter @InvexThera_ASX

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.



Invex Therapeutics

Bell Potter Healthcare Conference

Dr Tom Duthy, Executive Director

11 November 2021

ASX Code: IXC

Disclaimer

This presentation (**Presentation**) is issued by Invex Therapeutics Ltd (ASX:IXC) (the **Company** or **IXC**). The information presented in this Presentation may contain predictions, estimates and other forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, it can give no assurance that its goals will be achieved. This Presentation is not a disclosure document and is provided to the Recipient for the sole purpose of providing information relating to the investment opportunity described in this Presentation (**Purpose**). The Company will not be liable to compensate the Recipient for any costs or expenses incurred in reviewing, investigating or analysing any information, or in making an offer or otherwise. This Presentation is not to be taken to be an offer by any of the Investors to sell any or all of securities in the Company. This Presentation is provided for information purposes only and does not purport to contain all the information that may be required by each Recipient to evaluate any transaction in relation to the Purpose. In all cases, the Recipient should conduct its own investigation and analysis and should check the accuracy, reliability and completeness of the Information and obtain independent and specific advice from appropriate professional advisers. The information contained in this Presentation has been furnished by the Company and other sources deemed reliable but no assurance can be given by the Parties as to the accuracy or completeness of this information. To the full extent permitted by law: no representation or warranty (express or implied) is given; and no responsibility or liability (including in negligence) is accepted, by the Parties as to the truth, accuracy or completeness of any statement, opinion, forecast, information or other matter (whether express or implied) contained in this Presentation or its appendices or as to any other matter concerning them.



Company Snapshot



Company	
Repurposed, Proven Drug	Presendin™ (SR-Exenatide)
Clinical Stage	Phase III (Single Trial)
Orphan Disease Focus	Idiopathic Intracranial Hypertension (IIH)
Orphan Designation Granted	USA + EU/UK
Total Addressable Market	\$1.6 billion annually (USA/EU/UK)
Valuation Drivers	Clinical, regulatory, patent

Capital	
Shares on Issue	75.2 million
Unlisted Options	4.6 million
Ave. Quarterly Cash Burn (12 mth trailing)	\$0.49 million
Cash (30 Sep-21)	\$32.0 million
Market Capitalisation (8 Nov-21) ¹	\$49.6 million
Enterprise Value (8 Nov-21)	\$17.6 million

¹Based on a closing price of \$0.66

Major Shareholders (as at 18 October 2021)



Directors / Management	16.8%
Tattarang	11.8%
Tisia Nominees Pty Ltd	5.3%
Anthony Grist	4.0%
JK Nominees Pty Ltd	4.0%
University of Birmingham	2.7%

Top 20 Shareholders 59.4%

Board of Directors



Dr Jason Loveridge	Chairman
Professor Alexandra Sinclair	Executive Director & Chief Scientific Officer
Dr Tom Duthy	Executive Director
Mr David McAuliffe	Non-Executive Director
Dr Megan Baldwin	Non-Executive Director



Invex Therapeutics - Executive Summary

Clinical stage drug development Company targeting the orphan disease Idiopathic Intracranial Hypertension (IIH)

Attractive Market Dynamics



- IIH Total Addressable Market (TAM) in the US and EU/UK of **A\$1.6 billion** per annum (~A\$1 billion EU/UK, ~A\$0.6 billion US) and growing at **3.4% per annum**
- Unencumbered drug therapy market – no approved treatments, no new treatments in clinical trials
- Urgent market need, chronic administration required

Supportive Clinical Data



- Strong Phase II clinical data - clear statistical and clinical evidence of efficacy in primary and secondary endpoints demonstrating a strong and sustained drug effect in the IIH population
- No significant safety concerns over 12 weeks of treatment
- Phase III clinical trial commencing Q4 CY2021, targeting registration in the EU, UK and Australia

Significant Barriers to Competition



- Orphan drug designation in US (7 years exclusivity) and Europe (10 years exclusivity)
- Issued patents for use of Exenatide in IIH in US, EU and Japan out to beyond 2035



What is Idiopathic Intracranial Hypertension (IIH)?



The Disease¹

- >90% of cases are overweight women of childbearing age, with no known cause (idiopathic): approx. 4.7 per 100,000
- >90% suffer headaches that are progressively more severe and frequent: major cause of morbidity
- Up to 25% suffer permanent vision loss due to elevated intracranial pressure (ICP) effect on optic nerve function



The Impact²

- Invasive surgical and/or device interventions to temporarily lower ICP and preserve vision (significant side effects)
- 40% of patients have repeat hospital admissions, with average stays of 2.7 days
- Significant impact on quality of life and rapidly rising healthcare costs e.g. £462M in UK by 2030 (5x increase on 2017)




The Solution


- Prof. Alex Sinclair (Invex CSO & Exec. Director) first to demonstrate glucagon like peptide 1 (GLP-1) receptor agonists commonly used in diabetes treatment (Exenatide formulated as Byetta® or Bydureon®) act on the choroid plexus in the brain to lower cerebral spinal fluid secretion and as a consequence, ICP
- Exenatide - strong scientific basis for benefit, well defined mechanism of action, patents secured - re-purposing opportunity to improve safety & efficacy → Presendin™
- Invex Phase II Pressure Trial in IIH - first clear demonstration of safety & efficacy in IIH


IIH Total addressable market (TAM)


Key Inputs¹⁻⁵

 ~24,000 EU/UK patients

 ~16,000 US patients


 60% Diagnosed


 90% Drug Treatable


 4.3 year disease duration


 A\$1,500 cost per month*
*Example only (ref. drug pricing) – final market price for Presendin™ TBD

Market Size (Annual)

 ~A\$1.0 Billion

 ~A\$0.6 Billion

 ~A\$1.6 Billion

 3.4% growth

Market Drivers

 Increasing obesity rates

 Increasing awareness

 10% ↑ in diagnosis rate =
↑ A\$300 million in TAM

 >A\$2.3 Billion market by 2030



INITIAL TARGET MARKETS – EU, UK, AU

1. Mollan et al., EYE. The expanding burden of idiopathic intracranial hypertension (2019) incidence rate of 4.7/100,000 general population, n=23,182. Targets markets are EU 27(& UK) + USA

2. Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management (2018) ; Invex estimate re % presenting headache severity

3. Simoons et al., "what price do we pay for repurposing drugs for rare diseases"? (2016) – average 66x & Invex initial pricing analysis => pricing subject to change

4. D. Friesner et al., Idiopathic intracranial hypertension in the USA: the role of obesity in establishing prevalence and healthcare costs (2010)

5. Assumes average of obesity growth rates in UK (<https://www.oecd.org/els/health-systems/Obesity-Update-2017.pdf>) and historical incidence growth rate



Key clinician pathways in the management of IIH

No Immediate Threat to Vision

Optometrists



- Often patients with vision issues consult an optometrist, who in turn are primary referrers to ophthalmologists
- ~37,000 optometrists in the USA¹

Ophthalmologists



- ~19,000 ophthalmologists in the USA¹
- ~260 specialise in neuro-ophthalmology, specifically treating IIH patients²

Neurologists



- ~19,000 neurologists in the USA who see patients with significant headaches¹
- ~1,500 to 2,000 sub-specialise as certified headache specialists²



~40



~50



~355

Focussed target market of prescribers following first regulatory approvals for Presendin™ in EU, UK, AU


Threat to Vision




- Hospitalisation and surgical / device intervention
- CSF shunting, ONSF to reduce pressure




How IHT Treatment Could Change post Presendin™ Approval



Current




How IHT Treatment Could Change post Presendin™ Approval




Future

Idiopathic Intracranial Hypertension – Treatment Guidelines¹



Critical Components for Invex's Success



I Manufacturing

I Presendin™ Manufacturing Partnership

Exclusive Collaboration & Manufacturing Agreement with Peptron Inc. (South Korea)

- Executed 27 September 2021
- Worldwide collaboration, manufacturing and supply agreement for Presendin™ in Idiopathic Intracranial Hypertension (IIH)
- A 1x per week, sustained-release (SR) Exenatide microsphere formulation, originally developed by Peptron
- Exclusive manufacturing and supply to Invex for IIH in all major markets
- Peptron gains exclusive commercial rights for Presendin™ in South Korea for IIH
- Contract expires at the later of either the expiry of the last relevant Peptron patent or ten years following first commercial sale

Key Financial Terms

- Fixed price per dose for supply of Presendin™ and placebo for all Invex's clinical studies in IIH
- Fixed price per dose for supply of Presendin™ for commercial sale by Invex
- No royalties payable
- No upfront or milestone payments

I Benefits of Partnering for Manufacturing



STRATEGIC PARTNER

Establishes a long term strategic partner for Invex



TIME & RISK REDUCTION

Significant clinical and non-clinical data package provided by Peptron
12 months of lead-in activities no longer required to be performed by Invex
Significantly de-risking Invex's development of Presendin™ in IIH



PEPTRON EXPERTISE

Invex receives the benefit of Peptron's expertise and ongoing product development activities



FINANCIAL

~\$3M in Invex cost savings
Strong economics
- no royalties
- no milestone payments



MANUFACTURING

Financially robust
Commercial-scale capacity



PATIENTS

Once weekly dosing



I Clinical



IIH EVOLVE - a Phase III clinical trial evaluating the safety and efficacy of Presendin™ in IIH.

Designed based on substantial data analysis from previous IIH trials, extensive expert clinical and regulatory input, patient outreach, as well as scientific / protocol advice received from the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

- Randomised double-blinded, placebo controlled, multi-centre clinical trial to determine efficacy and safety of Presendin™ in IIH
 - ~37 centres planned to participate across Europe, the UK, the US and Australia
 - Investigational New Drug Application (IND) to be filed in the US
 - 240 patients with IIH to be randomised 1:1 versus placebo
 - Patients self-medicate with either a once weekly PLGA formulation of Exenatide (Presendin™) or placebo
 - Appointment of Key Trial Committees and Overall International Lead Investigator to be announced shortly
 - Recruitment anticipated to take up to 24 months
- Designed to meet the regulatory requirements for market approval of Presendin™ in the EU, UK and Australia
- Based on the Company's analysis of proprietary clinical data in IIH, the endpoints in IIH EVOLVE trial have sufficient statistical power to meet the primary outcome of Intracranial Pressure (ICP) along with the secondary endpoints of Perimetric Mean Deviation (PMD), papilloedema and Monthly Headache Days (MHD)
- Fully funded from Invex's existing cash on hand



Randomised double-blinded, placebo controlled multi-centre clinical trial to determine safety and efficacy of Presendin™ in IIH

Primary Endpoint

Change in Intracranial Pressure (ICP) from baseline at 24 weeks



Secondary Endpoint

Change in Perimetric Mean Deviation (PMD) from baseline over 24 weeks



Secondary Endpoint

Papilloedema (optic nerve swelling) by change in OCT¹ measures over 24 weeks



Secondary Endpoint

Change in Monthly Headache Days (MHD) from baseline over 24 weeks



Safety

Adverse events rate, anti-drug antibodies, PK and general lab measures




Quality of Life

Patient reported outcomes (SF-36, ED-5D-5L, VFQ-25), monthly patient diary



Phase III Schematic



1. OCT – Optical Coherence Tomography is an imaging tool accepted by professional bodies for monitoring papilloedema in IIH by measuring different aspects of the optic nerve. The optic nerve head size and retinal nerve fibre layer (RNFL) are measurements that both reflect swelling of the optic nerve and hence the extent of papilloedema. Optic nerve head measures on OCT correlate with visual field sensitivity loss.
2. s.c. – sub cutaneous

IIH EVOLVE Endpoint Assessment

Why ICP is Important



- A reduction in ICP is a requirement for approval by EMA
- Pure physical measurement
- Direct measurement of the mechanism of action of Presendin™
- Key diagnostic criteria of IIH

Why MHD is important



- >90% of IIH patients suffer from chronic headaches
- MHDs accepted clinically relevant endpoint by all regulators
- Headache has a detrimental effect on patient quality of life
- Headache management is an unmet need in IIH

Why PMD is Important



- Clinically meaningful measure used in prior IIH interventional trials as a primary endpoint
- Accepted clinically relevant endpoint by all regulators
 - PMD MCIC in IIH established by the Neuro-Ophthalmology Research Disease Investigator Consortium and the IIH Treatment Trial (IIHTT)
- Vision loss is the primary concern of all IIH clinicians

Why Papilloedema is important



- Measuring papilloedema is a vital measure clinically
- Key diagnostic criteria of IIH
- Change in papilloedema has been used by all randomised control trials in IIH to date to determine clinical improvement
- Measurement by OCT accepted in clinical practice and routinely used to monitor IIH patients all over the world – fast, objective



I Regulatory

I Regulatory




The Invex Phase III IIH EVOLVE clinical trial for Presendin™ is intended to support a European Medicines Agency (EMA), Medicines & Healthcare products Regulatory Agency (MHRA) and Therapeutic Goods Administration (TGA) approval for the treatment of IIH



- Strategy of seeking EU, UK and Australian market approvals ahead of the US based on a detailed risk based assessment following scientific advice and protocol assistance from both EMA and FDA
 - Informed by a detailed review of both published and proprietary IIH clinical data
- Selected approach is the lowest risk pathway
 - Global Phase III trial design difficult to achieve due to challenges in getting equivalence between the different regulatory agencies on endpoints and the definition of minimal clinically important change (MCIC)
- Outcomes from IIH EVOLVE will facilitate future discussions with the US FDA regarding registration of Presendin™ in the United States



Critical Pathways for Success



I Funding



I Funding



- \$26 million capital raise completed in May 2020
- Cash as at 30 September 2021: \$32 million
- Corporate overheads remain low: 9 months YTD total cash outflows of \$1.6 million with average quarterly cash burn of \$0.5 million
- Phase III trial fully costed and to be funded from existing cash reserves
- Cash runway sufficient to complete Phase III & market approvals (subject to clinical success)
- Cash burn to increase in coming periods as Phase III commences and contracts executed
- No additional capital required to achieve these milestones

I Summary & Outlook

- First clinical batches of Presendin™ from Peptron for IIH EVOLVE Phase III trial anticipated in Q4 CY2021
- Invex anticipates announcing the overall Lead International Investigator for the study and executing agreements with key service providers before the end of CY2021
- Single Phase III trial designed to support Presendin™ market approvals in the EU, UK and Australia
- First CTA for IIH EVOLVE to be submitted in Q4 CY2021
- Data generated from trial and inclusion of US sites will inform continued dialogue with FDA for future regulatory filings
- Potential for rapid incorporation of Presendin™ into IIH treatment guidelines
- IIH EVOLVE includes an economic evaluation to facilitate the health technology assessment (HTA) process – advantages with an orphan designation
- IIH EVOLVE fully funded from existing cash on hand (\$32 million as at 30 September 2021)
- Potentially first-ever regulatory approved drug for IIH in any jurisdiction world-wide
- A \$1 billion p.a. opportunity in the UK/EU and growing in-line with the obesity epidemic



invex
THERAPEUTICS

Thank you

Q&A

Contacts



INVESTORS

Dr Tom Duthy
Executive Director

+61 402 493 727
tduthy@invextherapeutics.com

MEDIA

Margie Livingston
Ignite Communications

+61 438 661 131
margie@ignitecommunications.com.au

To subscribe to Invex email alerts, please visit www.invextherapeutics.com
Follow us on Twitter @InvexThera_ASX

